If you have been reading about deamidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-04. Numbers and descriptions here follow the published literature rather than marketing material.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Purity assay | 95 percent or greater by RP-HPLC | Typical research-grade specification |
| Storage temperature | 2 to 8 degrees Celsius | Formulated solution, do not freeze |
| Common analytical method | LC-MS with peptide mapping | Identity and impurity confirmation |
| Primary degradation routes | Deamidation, oxidation, aggregation | Tracked in stability programs |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Orthogonal protection is a strategy allowing the specific deprotection of one protective group in a multiply-protected structure. For example, the amino acid tyrosine could be protected as a benzyl ester on the carboxyl group, a fluorenylmethylenoxy carbamate on the amine group, and a tert-butyl ether on the phenol group. The benzyl ester can be removed by hydrogenolysis, the fluorenylmethylenoxy group (Fmoc) by bases (such as piperidine), and the phenolic tert-butyl ether cleaved with acids (e.g. with trifluoroacetic acid). A common example for this application, the Fmoc peptide synthesis, in which peptides are grown in solution and on solid phase, is very important. The protecting groups in solid-phase synthesis regarding the reaction conditions such as reaction time, temperature and reagents can be standardized so that they are carried out by a machine, while yields of well over 99% can be achieved. Otherwise, the separation of the resulting mixture of reaction products is virtually impossible (see also § Industrial applications).
Polymer concentration affects fiber properties: an increase in polymer concentration decreases porosity and increases mechanical properties such as tensile strength. Solvent properties influence morphology of the scaffolds. After gelation, gel is placed in distilled water for solvent exchange. Afterwards, the gel is removed from the water and goes through freezing and freeze-drying. It is then stored in a desiccator until characterization.
== Function == GPVI is a 58-kD platelet membrane glycoprotein that plays a crucial role in the collagen-induced activation and aggregation of platelets. Upon injury to the vessel wall and subsequent damage to the endothelial lining, exposure of the subendothelial matrix to blood flow results in deposition of platelets. Collagen fibers are the most thrombogenic macromolecular components of the extracellular matrix, with collagen types I, III, and VI being the major forms found in blood vessels. Platelet interaction with collagen occurs as a 2-step procedure: (1) the initial adhesion to collagen is followed by (2) an activation step leading to platelet secretion, recruitment of additional platelets, and aggregation. In physiologic conditions, the resulting platelet plug is the initial hemostatic event limiting blood loss. However, exposure of collagen after rupture of atherosclerotic plaques is a major stimulus of thrombus formation associated with myocardial infarction or stroke. Complete or partial deficiency of GPVI in humans is a rare condition presenting as a mild bleeding disorder.
Hide glue is made from animal hide (animal skin) and is often used in woodworking. It may be supplied as granules, flakes, or flat sheets, which have an indefinite shelf life if kept dry. It is dissolved in water, heated and applied warm, typically around 60 °C (140 °F). Warmer temperatures quickly destroy the strength of hide glue. Commercial glue pots, simple water baths or double boilers may be used to keep the glue hot while in use. As hide glue cools, it gels quickly. At room temperature, prepared hide glue has the consistency of stiff gelatin, which is in fact a similar composition. Gelled hide glue does not have significant strength, so it is vital to apply the glue, fit the pieces, and hold them steady before the glue temperature drops much below 50 °C (120 °F). All glues have an open time, the amount of time the glue remains liquid and workable. Joining parts after the open time is expired results in a weak bond. Hide glue's open time is usually a minute or less. In practice, this often means having to heat the pieces to be glued, and gluing in a very warm room, though these steps can be dispensed with if the glue and clamp operation can be carried out quickly. Where hide glue is in occasional use, excess glue may be held in a freezer, to prevent spoilage from the growth of microorganisms. Hide glue has some gap filling properties, although modern gap-filling adhesives, such as epoxy resin, are better in this regard. Hide glue that is liquid at room temperature is also possible through the addition of urea.
Sources: en.wikipedia.org
Samarium-151 (151Sm) has a half-life of 94.6 years, undergoing low-energy beta decay, and has a fission product yield of 0.4203% for thermal neutrons and 235U, about 39% of 149Sm's yield. The yield is somewhat higher for 239Pu. Its neutron absorption cross section for thermal neutrons is high at 15200 barns, about 38% of 149Sm's absorption cross section, or about 20 times that of 235U. Since the ratios between the production and absorption rates of 151Sm and 149Sm are almost equal, the two isotopes should reach similar equilibrium concentrations. Since 149Sm reaches equilibrium in about 500 hours (20 days), 151Sm should reach equilibrium in about 50 days. As this is still much shorter than its radioactive half-life, decay will hardly affect this equilibrium while in the reactor. Since nuclear fuel is used for several years (burnup) in a nuclear power plant, the final amount of 151Sm in the spent nuclear fuel at discharge is only a small fraction of the total 151Sm produced during the use of the fuel. According to one study, the mass fraction of 151Sm in spent fuel is about 0.0025 for heavy loading of MOX fuel and about half that for uranium fuel, which is roughly two orders of magnitude less than the mass fraction of about 0.15 for the medium-lived fission product 137Cs. The decay energy of 151Sm is also about an order of magnitude less than that of 137Cs. The low yield, low survival rate, and low decay energy mean that 151Sm has insignificant nuclear waste impact compared to the two main medium-lived fission products 137Cs and 90Sr.
== External links == "Rosiglitazone". MedlinePlus. U.S. National Library of Medicine. Peck P (20 July 2004). "Rosiglitazone May Improve Function in Patients With Mild Alzheimer's Disease". Medscape. "Rosiglitazone". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on May 11, 2009.
On September 26, 2020, an event was held in the White House Rose Garden announcing Amy Coney Barrett's nomination to the Supreme Court following the death of Ruth Bader Ginsburg. According to a 2021 book by Trump's Chief of Staff Mark Meadows, hours after the ceremony, Trump tested positive for COVID-19, although a subsequent test returned negative. Meadows recalled that Trump looked "a little tired" and was suspected of having a "slight cold". Trump later traveled in Air Force One to a rally at the Harrisburg International Airport in Pennsylvania, which was attended by thousands. After Trump's diagnosis was made public, Pennsylvania health officials advised attendees to participate in the state's contact tracing program. After returning from Bedminster, Trump received a positive test result on a rapid test and was waiting to get results of a PCR test when he did a live phone interview on Hannity. On October 2, 2020, Trump tweeted that he and his wife Melania Trump had both tested positive for COVID-19, part of a White House outbreak. Later that day, Trump was hospitalized at Walter Reed National Military Medical Center, reportedly due to fever and labored breathing. He was treated with antivirals, an experimental antibody drug (REGN-COV2), and a steroid. He returned to the White House on October 5, still infectious and unwell. In 2021, it was revealed that his condition had been far more serious than he had previously indicated; he had dangerously low blood oxygen levels, a high fever, and lung infiltrates, indicating a severe case of COVID-19.
==== Other musculoskeletal disorders ==== There is limited, low-quality evidence of a slight benefit of noxious-level electrotherapy in the treatment of epicondylitis. A 2012 review found that "Small, single studies showed that some electrotherapy modalities may be beneficial" in rehabilitating ankle bone fractures, but the 2024 update of this review does not address electrotherapy. However, a 2008 review found it to be ineffective in healing long-bone fractures. A 2012 review found that evidence that electrotherapy contributes to recovery from knee conditions is of "limited quality".
The first steps to digitization in trucking came in the form of digital freight exchanges such as Teleroute and TIMOCOM. Greater efficiency in trucking is being achieved through intelligent freight technology such as automated interfaces that can help truckers and regulatory bodies reduce stops at weigh stations and time spent at border checkpoints. This improves schedule adherence, reduces administrative burdens, and increases fuel efficiency by minimizing time spent idling. Mobile tracking programs can also reduce theft and loss of cargo by recording instances where trailer doors are opened outside of approved areas (geo-fences) and alerting authorities. Growing automation of quoting and booking of truckload shipments and increased automation of matching trucks with appropriate loads in a timely manner is also working to maximize efficiency for shippers and consumers. Cargofy is an example of a freight technology company using artificial intelligence to automate freight procurement, load matching, dispatching and other logistics operations. Vehicle tracking has been used by shipping agents and freight forwarders to monitor the location of vehicles. They can also monitor traffic information, vehicle and driver data, and other real-time freight information. Due to the relatively short life cycle of three to four years for commercial trucks, implementation of new interfaces and freight technologies has progressed more quickly in trucking than in other sectors.
Sources: en.wikipedia.org
== Chemical structure == COP is formed by ring-opening metathesis polymerization (ROMP) of cyclic olefin monomers such as norbornene, followed by partial or total hydrogenation. Modification of the monomer structure results in polymers with a range of glass transition temperatures, stiffness and viscosities. Commercial products include Zeon Chemical's ZEONEX® and ZEONOR® and Japan Synthetic Rubber's ARTON. An alternative process involving copolymerization with ethylene is used to make cyclic olefin copolymers (COC). These two types of cyclic olefin polymers were historically referred to as COC but are now recognized as distinct classes of polymers formed from different polymerization processes. Commercial products include Mitsui Chemical's APEL™ and TOPAS Advanced polymers' TOPAS® COC. Though they share many of the same physical properties, cyclic olefin polymer (COP) formed by ROMP offers greater transparency and mechanical stability and its surface is more amenable to plasma treatment for optimizing cell growth.
The National Institute for Health and Care Excellence now recommends closed-loop insulin systems as an option for all women with type 1 diabetes who are pregnant or planning pregnancy. A non-insulin medication approved by the U.S. Food and Drug Administration for treating type 1 diabetes is the amylin analog pramlintide, which replaces the beta-cell hormone amylin. The addition of pramlintide to mealtime insulin injections reduces the boost in blood sugar after a meal, improving blood sugar control. Occasionally, metformin, GLP-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, or SGLT2 inhibitor are prescribed off-label to people with type 1 diabetes. Fewer than 5% of people with type 1 diabetes use these drugs.
== See also == Gonadotropin-releasing hormone receptor § Agonists GnRH modulator Progonadotropin Gonadotropin surge-attenuating factor GNRH2, a similar gene Gonadotropin-inhibitory hormone Breastfeeding and fertility
== Company profile == Camurus aims to collaborate with biotechnology and pharmaceutical companies worldwide to enable and improve the delivery of a wide range of drug compounds. These compounds including peptides, proteins, and insoluble small molecules make use of delivery solutions ranging from long-acting depots to lipid nanocarriers designed for improved intravenous, transdermal, and oral delivery. Camurus' in-house product portfolio targets healthcare needs in areas of growth-hormone disorders, cancer, oncology supportive care, metabolic disease, and drug addiction.
The layer was first discovered by the use of scanning transmission electron microscopy (STEM), however the images taken did not have resolution high enough to determine the precise location of the silica. Some investigators hypothesize that the layer helps different spores from sticking together. It has also been shown to provide some resistance to acidic environments. The silica coat is related to the permeability of the spore's inner membrane. Strong mineral acids are able to break down spore permeability barriers and kill the spore. However, when the spore has a silica coating, it may reduce the permeability of the membrane and provide resistance to many acids.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.
Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.
Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.